Alagille Syndrome

23 registered clinical trials studyying Alagille Syndrome — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille NCT07290257	Mirum Pharmaceuticals, Inc.	Phase 4
Recruiting	A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syn NCT06850038	Ipsen	—
Recruiting	Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) NCT06193928	Mirum Pharmaceuticals, Inc.	—
Unknown	Decreasing Hemorrhage Risk in Children With Alagille Syndrome NCT05846854	Stanford University	N/A
Completed	Atorvastatin Therapy on Xanthoma in Alagille Syndrome NCT05488067	Children's Hospital of Fudan University	Phase 4
Completed	A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver D NCT04729751	Mirum Pharmaceuticals, Inc.	Phase 2
Recruiting	Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome NCT05035030	Albireo, an Ipsen Company	Phase 3
Completed	Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome NCT04674761	Albireo	Phase 3
Completed	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects NCT03082937	Albireo	Phase 1
Completed	FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE) NCT02922751	Arbor Research Collaborative for Health	—
Completed	An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cho NCT02117713	Mirum Pharmaceuticals, Inc.	Phase 2
Completed	Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome NCT02057692	Mirum Pharmaceuticals, Inc.	Phase 2
Completed	Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille NCT02160782	Mirum Pharmaceuticals, Inc.	Phase 2
Completed	Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease NCT02131623	Mirum Pharmaceuticals, Inc.	—
Completed	An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cho NCT02047318	Mirum Pharmaceuticals, Inc.	Phase 2
Completed	Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Sy NCT01903460	Mirum Pharmaceuticals, Inc.	Phase 2
Completed	A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 NCT02963077	Albireo	Phase 1
Recruiting	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168	Sanford Health	—
Suspended	Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) NCT00571272	Arbor Research Collaborative for Health	—
Completed	Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review NCT01515631	Stanford University	—
Completed	Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Diseas NCT00007033	National Center for Research Resources (NCRR)	N/A
Completed	Positional Cloning of the Gene(s) Responsible for Alagille Syndrome NCT00001642	National Human Genome Research Institute (NHGRI)	—
Approved For Marketing	A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome NCT04530994	Mirum Pharmaceuticals, Inc.	—